Author:
Hannawi Suad,Wu Xiao-Hong,Villalobos Ralph Elvi,Burhan Erlina,Lallaine Borra Ma. Dovie,Gupta Rakesh Kumar,Aquitania Grace P.,Ang Blake Warren C.,Mae A. Zabat Gelza,Roa Camilo C.,Zoleta-De Jesus Loreta,Yu Dan-Dan,Wang Meng,Wu Yan,Song Wen-Jie,Ying Bo,Qin Cheng-Feng
Reference38 articles.
1. Alarming antibody evasion properties of rising SARS-COV-2 BQ and XBB subvariants;Wang;Cell,2023
2. Neutralization against XBB.1 and XBB.1.5 after Omicron subvariants breakthrough infection or reinfection;Chen;Lancet Reg. Health. West. Pac.,2023
3. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate;Uraki;Lancet Infect. Dis.,2023
4. Weekly epidemiological update on COVID-19-30 March 2023,2023
5. Low neutralization of SARS-COV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster;Kurhade;Nat. Med.,2023